These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15772071)

  • 1. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.
    Feldman RI; Wu JM; Polokoff MA; Kochanny MJ; Dinter H; Zhu D; Biroc SL; Alicke B; Bryant J; Yuan S; Buckman BO; Lentz D; Ferrer M; Whitlow M; Adler M; Finster S; Chang Z; Arnaiz DO
    J Biol Chem; 2005 May; 280(20):19867-74. PubMed ID: 15772071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.
    Falasca M; Chiozzotto D; Godage HY; Mazzoletti M; Riley AM; Previdi S; Potter BV; Broggini M; Maffucci T
    Br J Cancer; 2010 Jan; 102(1):104-14. PubMed ID: 20051961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
    Gagliardi PA; di Blasio L; Orso F; Seano G; Sessa R; Taverna D; Bussolino F; Primo L
    Neoplasia; 2012 Aug; 14(8):719-31. PubMed ID: 22952425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
    Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
    Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule inhibitors of PDK1.
    Peifer C; Alessi DR
    ChemMedChem; 2008 Dec; 3(12):1810-38. PubMed ID: 18972468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth.
    Qin L; Tian Y; Yu Z; Shi D; Wang J; Zhang C; Peng R; Chen X; Liu C; Chen Y; Huang W; Deng W
    Oncotarget; 2016 Jan; 7(2):1395-407. PubMed ID: 26593251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
    Yang L; Dan HC; Sun M; Liu Q; Sun XM; Feldman RI; Hamilton AD; Polokoff M; Nicosia SV; Herlyn M; Sebti SM; Cheng JQ
    Cancer Res; 2004 Jul; 64(13):4394-9. PubMed ID: 15231645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
    Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
    J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of high-throughput TR-FRET and AlphaScreen assays for identification of potent inhibitors of PDK1.
    Xu Z; Nagashima K; Sun D; Rush T; Northrup A; Andersen JN; Kariv I; Bobkova EV
    J Biomol Screen; 2009 Dec; 14(10):1257-62. PubMed ID: 19822882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New inhibitor of 3-phosphoinositide dependent protein kinase-1 identified from virtual screening.
    Yang W; AbdulHameed MD; Hamza A; Zhan CG
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1629-32. PubMed ID: 22266037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
    Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
    Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling.
    Thimmaiah KN; Easton JB; Germain GS; Morton CL; Kamath S; Buolamwini JK; Houghton PJ
    J Biol Chem; 2005 Sep; 280(36):31924-35. PubMed ID: 16009706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
    Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells.
    Tamgüney T; Zhang C; Fiedler D; Shokat K; Stokoe D
    Exp Cell Res; 2008 Jul; 314(11-12):2299-312. PubMed ID: 18514190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
    Mallon R; Hollander I; Feldberg L; Lucas J; Soloveva V; Venkatesan A; Dehnhardt C; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Gibbons J
    Mol Cancer Ther; 2010 Apr; 9(4):976-84. PubMed ID: 20371716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.
    Nagashima K; Shumway SD; Sathyanarayanan S; Chen AH; Dolinski B; Xu Y; Keilhack H; Nguyen T; Wiznerowicz M; Li L; Lutterbach BA; Chi A; Paweletz C; Allison T; Yan Y; Munshi SK; Klippel A; Kraus M; Bobkova EV; Deshmukh S; Xu Z; Mueller U; Szewczak AA; Pan BS; Richon V; Pollock R; Blume-Jensen P; Northrup A; Andersen JN
    J Biol Chem; 2011 Feb; 286(8):6433-48. PubMed ID: 21118801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.